Michael Endl, MD
Ophthalmology · Amherst, NYNPI 1811992019
Payments from drug & device makers
Across 568 payments — averaging $671.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch Health US, LLC$156K
- AbbVie$57K
- Bausch & Lomb Americas Inc.$52K
- Sight Sciences, Inc.$27K
- Kala Pharmaceuticals, Inc.$27K
- Rayner Intraocular Lenses Limited$24K
- plus $39K from 23 others
Across 8 payments — averaging $47,814 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bausch & Lomb Americas Inc.$369K
- Bausch Health US, LLC$13K
What the payments were for
- Consulting fees$52,32834%
- Speaking & faculty fees$74,91849%
- Travel & lodging$7,3465%
- Food & beverage$17,20211%
- Education$1130%
- Gifts$360%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch Health US, LLC | 13 | $156,102 |
| AbbVie(2 entities) | 123 | $57,251 |
| Bausch & Lomb Americas Inc. | 48 | $51,850 |
| Sight Sciences, Inc. | 71 | $27,208 |
| Kala Pharmaceuticals, Inc. | 51 | $26,534 |
| Rayner Intraocular Lenses Limited | 19 | $24,120 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 14 | $14,747 |
| Omeros Corporation | 15 | $10,177 |
| Carl Zeiss Meditec USA, Inc. | 22 | $7,001 |
| Alcon | 82 | $2,440 |
| Ivantis, Inc | 14 | $1,959 |
| Sun Pharmaceutical Industries Inc. | 31 | $617 |
| Johnson & Johnson Surgical Vision, Inc. | 12 | $372 |
| Glaukos Corporation | 4 | $215 |
| Biotissue Holdings Inc. | 8 | $143 |
| Ocular Therapeutix, Inc. | 7 | $139 |
| Rxsight Inc | 2 | $127 |
| Carl Zeiss Meditec, Inc. | 2 | $118 |
| Tarsus Pharmaceuticals, Inc. | 5 | $111 |
| Oyster Point Pharma, Inc. | 6 | $111 |
| Harrow Eye, LLC | 4 | $84 |
| Dompe US, Inc. | 3 | $60 |
| Novartis | 4 | $58 |
| Aerie Pharmaceuticals, Inc. | 2 | $33 |
| Mallinckrodt Hospital Products Inc. | 1 | $33 |
| Amgen | 1 | $22 |
| Thea Pharma Inc. | 1 | $19 |
| Eyevance Pharmaceuticals LLC | 1 | $15 |
| NEW World Medical,inc. | 2 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OMNI(R) SURGICAL SYSTEM (US)$25,186
- EYSUVIS$17,955
- DURYSTA$17,444
- RayOne EMV$15,449
- RayOne Spheric$15,449
- RayOne Aspheric$15,449
- VICTUS$14,239
- OMIDRIA$14,015
- INVELTYS$8,361
- VisuMax$4,701
- SION SURGICAL INSTRUMENT$3,142
- TENEO$2,450
- Hydrus$1,036
- MEL 90$1,020
- Hydrus Microstent$813
- RESTASIS$750
- OMNI$605
- ReSTOR$150
- TEARCARE SYSTEM$148
- IC-8 Apthera IOL$147
How this compares
$381,672 in reported general payments places this provider in the 95th percentile of 1,587 ophthalmology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 14 | $392,230 |
| XiidraLifitegrast | 115 | $171,586 |
| RestasisCyclosporine | 100 | $163,323 |
| Cyclosporine | 202 | $145,813 |
| LumiganBimatoprost | 112 | $65,934 |
| CequaCyclosporine | 26 | $27,606 |
| Loteprednol Etabonate | 150 | $23,731 |
| Brimonidine Tartrate | 194 | $23,369 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 62 | $15,158 |
| Prednisolone Acetate | 268 | $11,964 |
| Latanoprost | 671 | $11,919 |
| Travoprost | 48 | $11,677 |
| Alphagan PBrimonidine Tartrate | 24 | $10,603 |
| VyzultaLatanoprostene Bunod | 25 | $10,216 |
| RocklatanNetarsudil Mesylat/Latanoprost | 20 | $9,462 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dompe US, Inc.Oxervate | $60 | $392,23014 claims |
| AbbVieRestasis, Lumigan, Alphagan P, Combigan | $57,251 | $245,624253 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $51,850 | $181,802140 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $617 | $27,60626 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $14,747 | $23,731150 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $33 | $9,46220 claims |
| AlconSimbrinza | $2,440 | $8,07334 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,587 ophthalmology providers in New York.
Other ophthalmology in Amherst
- Douglas JabsNew York$24.3M
- David RubaltelliBrooklyn$8.9M
- Philip FerroneGreat Neck$5.8M
- Eric DonnenfeldGarden City$2.6M
- Nathan RadcliffeNew York$2.4M
- Glenn StollerRockville Centre$2.1M
- Richard SpaideNew York$1.7M
- Paul HartmanRochester$1.6M
- Jason SlakterNew York$1.2M
- David ChuNew York$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.